Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
RDHL moved a median of -0.50% 30 minutes after news, and -0.82% by the close. How RDHL actually reacts to news — the realized, point-in-time move the market made, measured across 143 labeled events over the last three years with zero look-ahead.
RDHL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 141 |
| 30-min | -0.50% | 39% | 142 |
| 60-min | -0.80% | 42% | 143 |
| to close | -0.82% | 44% | 142 |
| Middle 50% of RDHL reactions | -3.11% to +1.60% |
|---|---|
| Median reaction (30-min) | -0.50% |
| Measured reactions | 143 |
Half of all Redhill Biopharma Ltd. - American Depositary Shares news events land between -3.11% and +1.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RDHL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RDHL's baseline. Nothing else.
Recent RDHL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results | Press release | PR Newswire | +2.17% | +3.23% | |
| RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® | Press release | PR Newswire | -3.64% | -1.36% | |
| RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq® | Press release | GlobeNewswire | -3.64% | -1.36% | |
| RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Press release | Canada Newswire | +4.32% | -35.25% | |
| Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development | Press release | PR Newswire | -2.78% | +1.39% | |
| RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement | Press release | PR Newswire | +0.60% | +10.90% | |
| RedHill Biopharma Announces Up To $19.4 Million Private Placement | Press release | PR Newswire | +2.16% | +2.75% | |
| RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | Press release | PR Newswire | -10.81% | -11.10% | |
| RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo | Press release | PR Newswire | -7.69% | -0.97% | |
| RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Press release | PR Newswire | -3.10% | +0.41% | |
| RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms | Press release | PR Newswire | -0.98% | -0.98% | |
| RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease | Press release | PR Newswire | -0.47% | +2.83% | |
| RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +0.00% | +0.98% | |
| RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | Press release | PR Newswire | +2.80% | +2.78% | |
| H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight | Press release | PR Newswire | +1.05% | -0.47% | |
| Joint U.S. Commercialization of RedHill's Talicia® Commences | Press release | PR Newswire | +4.59% | -4.00% | |
| RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects | Press release | PR Newswire | +0.42% | +16.67% | |
| RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Press release | PR Newswire | -1.64% | -2.46% | |
| RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement | Press release | PR Newswire | +4.00% | +3.33% | |
| RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement | Press release | PR Newswire | +16.00% | -13.60% | |
| RedHill Biopharma Receives Nasdaq Staff Determination Notification | Press release | PR Newswire | +3.62% | +4.22% | |
| RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal | Press release | PR Newswire | -10.15% | -14.36% | |
| RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® | Press release | PR Newswire | -0.29% | -7.87% | |
| RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo | Press release | PR Newswire | -3.53% | -8.23% | |
| RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +0.01% | +16.55% | |
| RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win | Press release | PR Newswire | -1.44% | — | |
| RedHill Received Talicia® Licensing Payments Totaling $1.1 Million | Press release | PR Newswire | -4.22% | +1.41% | |
| RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | Press release | PR Newswire | -5.12% | +0.43% | |
| RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer | Press release | PR Newswire | +1.79% | +1.51% | |
| RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win | Press release | PR Newswire | -10.66% | -4.06% | |
| RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress | Press release | PR Newswire | +0.23% | -3.72% | |
| RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 | Press release | PR Newswire | -0.42% | -9.21% | |
| RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency | Press release | PR Newswire | -0.50% | +7.96% | |
| RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption | Press release | PR Newswire | +9.59% | +20.35% | |
| RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights | Press release | PR Newswire | -3.22% | -1.07% | |
| RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation | Press release | PR Newswire | -3.33% | +0.35% | |
| RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results | Press release | PR Newswire | +2.75% | +3.47% | |
| RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum | Press release | PR Newswire | +0.00% | -5.26% | |
| RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties | Press release | PR Newswire | -3.60% | -23.42% | |
| RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer | Press release | PR Newswire | +5.92% | -1.52% | |
| RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published | Press release | PR Newswire | +0.00% | +1.44% | |
| Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development | Press release | PR Newswire | — | +4.24% | |
| RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court | Press release | PR Newswire | +1.74% | -4.77% | |
| RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND | Press release | PR Newswire | -0.24% | +0.37% | |
| RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury | Press release | PR Newswire | +0.00% | -4.14% | |
| RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment | Press release | PR Newswire | -0.25% | -0.62% | |
| RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians | Press release | PR Newswire | +0.00% | -4.16% | |
| RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 | Press release | PR Newswire | +0.00% | +1.28% | |
| RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines | Press release | PR Newswire | +3.31% | +9.81% | |
| RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | PR Newswire | -2.19% | +3.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RDHL section they belong to.
Where else RDHL is measured.
RDHL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cara Therapeutics, Inc. (CARA) | 143 | -0.56% | 46% |
| Nutriband Inc. (NTRB) | 143 | 0.00% | 44% |
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Redhill Biopharma Ltd. - American Depositary Shares's median reaction calculated?
Every labeled RDHL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 143 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of RDHL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RDHL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.